286 related articles for article (PubMed ID: 21822560)
1. The immunological impact of neoadjuvant chemotherapy on the tumor microenvironment of esophageal squamous cell carcinoma.
Tsuchikawa T; Miyamoto M; Yamamura Y; Shichinohe T; Hirano S; Kondo S
Ann Surg Oncol; 2012 May; 19(5):1713-9. PubMed ID: 21822560
[TBL] [Abstract][Full Text] [Related]
2. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes before and after neoadjuvant chemotherapy in cervical cancer.
Liang Y; Lü W; Zhang X; Lü B
Diagn Pathol; 2018 Nov; 13(1):93. PubMed ID: 30474571
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
4. Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma.
Okamura A; Watanabe M; Mine S; Kurogochi T; Yamashita K; Hayami M; Imamura Y; Ogura M; Ichimura T; Takahari D; Chin K
Dis Esophagus; 2017 Sep; 30(9):1-8. PubMed ID: 28859367
[TBL] [Abstract][Full Text] [Related]
5. CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer.
Zhu Y; Li M; Mu D; Kong L; Zhang J; Zhao F; Li Z; Liu X; Bo C; Yu J
Oncotarget; 2016 Nov; 7(44):71455-71465. PubMed ID: 27683115
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors in Patients Receiving Neoadjuvant 5-Fluorouracil plus Cisplatin for Advanced Esophageal Cancer (JCOG9907).
Yokota T; Ando N; Igaki H; Shinoda M; Kato K; Mizusawa J; Katayama H; Nakamura K; Fukuda H; Kitagawa Y
Oncology; 2015; 89(3):143-51. PubMed ID: 25895447
[TBL] [Abstract][Full Text] [Related]
7. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
9. [Three cases of esophageal carcinoma achieved a pathological complete response after neoadjuvant chemotherapy with cisplatin and 5-fluorouracil].
Oyanagi H; Ichikawa H; Kosugi S; Banba T; Hanyu T; Hirashima K; Ishikawa T; Kameyama H; Kobayashi T; Minagawa M; Koyama Y; Wakai T
Gan To Kagaku Ryoho; 2015 Apr; 42(4):497-501. PubMed ID: 25963701
[TBL] [Abstract][Full Text] [Related]
10. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
[TBL] [Abstract][Full Text] [Related]
12. Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival.
Tsuchikawa T; Ikeda H; Cho Y; Miyamoto M; Shichinohe T; Hirano S; Kondo S
Clin Exp Immunol; 2011 Apr; 164(1):50-6. PubMed ID: 21352198
[TBL] [Abstract][Full Text] [Related]
13. The clinical efficacy of neoadjuvant chemotherapy in squamous esophageal cancer: a prospective nonrandomized study of pulse and continuous-infusion regimens with Cisplatin and 5-Fluorouracil.
Chan AC; Lee DW; Griffith JF; Leung SF; Lam YH; Lam CC; Lau JY; Ng EK; Chung SC
Ann Surg Oncol; 2002 Aug; 9(7):617-24. PubMed ID: 12167574
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the prognostic value of the 6th and 7th editions of the Union for International Cancer Control TNM staging system in patients with lower esophageal cancer undergoing neoadjuvant chemotherapy followed by surgery.
Mehta SP; Jose P; Mirza A; Pritchard SA; Hayden JD; Grabsch HI
Dis Esophagus; 2013; 26(2):182-8. PubMed ID: 22591020
[TBL] [Abstract][Full Text] [Related]
16. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy.
Miyata H; Yoshioka A; Yamasaki M; Nushijima Y; Takiguchi S; Fujiwara Y; Nishida T; Mano M; Mori M; Doki Y
Cancer; 2009 Jul; 115(14):3324-34. PubMed ID: 19452547
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of esophageal squamous cell carcinoma in patients positive for human epidermal growth factor receptor family can be improved by initial chemotherapy with docetaxel, fluorouracil, and cisplatin.
Yamamoto Y; Yamai H; Seike J; Yoshida T; Takechi H; Furukita Y; Kajiura K; Minato T; Bando Y; Tangoku A
Ann Surg Oncol; 2012 Mar; 19(3):757-65. PubMed ID: 21947696
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy with etoposide, leucovorin, 5-fluorouracil and cisplatin for advanced esophageal squamous cell carcinoma.
Ohwada S; Nakamura S; Izumi M; Kawashima Y; Ogawa T; Kobayashi I; Hosomura Y; Joshita T; Lino Y; Morishita Y
Jpn J Clin Oncol; 1995 Jun; 25(3):79-85. PubMed ID: 7596052
[TBL] [Abstract][Full Text] [Related]
20. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma.
Cao XF; He XT; Ji L; Xiao J; Lv J
Dis Esophagus; 2009; 22(6):477-81. PubMed ID: 19703071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
